Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus.

Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus. Abstract Text:

,

Previous US Public Health Service recommendations pertaining to sexual, IV drug abuse, and perinatal transmission of human-T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) have been published. Reduction of sexual and IV transmission of HTLV-III/LAV should be enhanced by using available serologic tests to give asymptomatic, infected individuals in high-risk groups the opportunity to know their status so they can take appropriate steps to prevent the further transmission of this virus. Since the objective of these additional recommendations is to help interrupt transmission by encouraging testing and counseling among persons in high-risk groups, careful attention must be paid to maintaining confidentiality and to protecting records from any unauthorized disclosure. The ability of health departments to assure confidentiality, and the public confidence in that ability, are crucial to efforts to increase the number of persons requesting such testing and counseling. Persons at increased risk of HTLV-III/LAV infection include: homosexual and bisexual men; present or past IV drug abusers; persons with clinical or laboratory evidence of infection, such as those with signs or symptoms compatible with acquired immune deficiency syndrome (AIDS) or AIDS-related complex (ARC); persons born in countries where heterosexual transmission is thought to play a major role; male or female prostitutes and their sex partners; sex partners of infected persons or persons at increased risk; all persons with hemophilia who have received clotting-factor products; and newborn infants of high-risk or infected mothers. Recommendations include: community health education programs should be aimed at members of high-risk groups to increase knowledge of AIDS, to facilitate behavioral changes to reduce risks of HTLV-III/LAV infection, and encourage voluntary testing and counseling; counseling and voluntary serologic testing for HTLV-III/LAV should be routinely offered to all persons at increased risk when they present to health care settings; infected patients should be encouraged to refer sex partners or persons with whom they have shared needles to their health care providers for evaluation and/or testing; persons with a negative test should be counseled about their need for continued evaluation to monitor their infection status if they continue high-risk behavior; state and local health officials should evaluate the implications of requiring the reporting of repeatedly reactive HTLV-III/LAV antibody test results to the state health department; and state or local action is appropriate on public health grounds to regulate or close establishments where there is evidence that they facilitate high-risk behaviors.

Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus. Publishing Authors By Initials

,

For similar disorders of environmental origin: substance-related disorders research abstracts see: disorders of environmental origin: substance-related disorders research

PUBMED ID PMID:

MEDLINE DATE:

Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: MMWR. Morbidity and mortality weekly report

VOLUME: 35

Page Numbers: 152-5

Journal Abbreviation: MMWR Morb. Mortal. Wkly. Rep.

ISSN: 0149-2195

DAY: 14

MONTH: Mar

YEAR: 1986

Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7802429

Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus. Keywords Mesh Terms:

KEYWORDS: Substance-Related Disorders

MESH TERMS: complications

Chemical & Substance for Abstract: Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus. Information

Substance Name: Antibodies, Viral

Registry Number: 0

Grant and Affiliation Information for Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus.

AFFILIATION:

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: MMWR Morb Mortal Wkly Rep

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus Related Publications